| ￥5800 | |
| Z04567-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Conjugate | Biotin | ||||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized NKG2A/CD159a[Biotin], His & Avi, Human at 1μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml) can bind Anti?NKG2A Antibody, hFc Tag. Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 18.3 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized NKG2A/CD159a[Biotin], His & Avi, Human, His Tag at 1 μg/ml (100 μl/well) on the streptavidin precoated plate(5 μg/ml). Dose response curve for Anti-NKG2A Antibody, hFc Tag with the EC50 of 5.3 ng/ml determined by ELISA. ?
NKG2A/CD159a[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. ?
| Target Background | NKG2, also known as NKG2A(CD159A), is a member of the killer cell lectin-like receptor family. NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors.It is expressed only in NK-cells, but not in T-cells or B-cells. |
| Synonyms | NKG2A; NKG2-A; CD94; KLRD1; KP43; KLRC1; CD159A |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
